Amondys 45 market seen expanding on genetic medicine and rare disease demand

The Business Research Company says the Amondys 45 market is set to grow through 2035 as genetic testing, personalized medicine and rare-disease treatment adoption accelerate. North America led the market in 2025, while Europe is expected to post the fastest growth.

Why it matters: - Amondys 45 is a targeted treatment for Duchenne muscular dystrophy, so demand tracks broader progress in rare-disease diagnosis and precision medicine. - The market outlook points to more investment in exon-skipping therapies, regulatory support for orphan drugs and earlier treatment of genetically matched patients. - The report’s projections suggest the therapy’s commercial prospects are tied to expanding use of genetic testing and newborn screening.

What happened: - The Business Research Company published its Amondys 45 Market Report 2026, covering market size, trends and a global forecast for 2026-2035. - The report says the Amondys 45 market gained traction as advances in genetic medicine and diagnostic technologies improved treatment options for Duchenne muscular dystrophy. - The company released a free sample of the report and a full report download link: sample request and full market report.

The details: - Amondys 45, or casimersen, is an FDA-approved prescription medicine for patients with Duchenne muscular dystrophy who have a mutation amenable to exon 45 skipping. - The therapy uses an antisense oligonucleotide approach to skip exon 45 during gene transcription, enabling production of a functional but shortened dystrophin protein. - The report links historical market growth to limited DMD treatment options, orphan-drug incentives, wider genetic testing access, early antisense research and patient advocacy. - Expected growth drivers include gene-based therapy innovation, newborn screening expansion, exon-specific drug development, regulatory fast-tracking and higher clinical-trial investment. - The report highlights rising demand for exon-skipping therapies, precision genetic medicine, earlier diagnosis and stronger orphan-drug support as key trends. - The report says increasing prevalence of genetic disorders is pushing demand for targeted therapies. - Australia’s National Blood Authority reported hereditary haemophilia A cases rising from 2,681 in 2022-2023 to 2,788 in 2023-2024, cited in the release as an example of growing need for genetic therapies. - The release also points to rising healthcare spending as a tailwind for advanced treatments. - The UK Office for National Statistics reported total healthcare expenditure rose 5.6% nominally from 2022 to 2023, compared with 0.9% growth in the prior year. - Personalized medicine is another growth driver as genomic tools make it easier to match therapies to specific mutations. - The Personalized Medicine Coalition said the FDA approved 26 new personalized medicines in 2023, up from 12 in 2022. - North America led the global Amondys 45 market in 2025. - Europe is expected to grow the fastest over the forecast period. - The report covers Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The 2026 report edition adds market attractiveness scoring, total addressable market analysis, a company scoring matrix, Excel forecasting dashboards, market-hotspot infographics and updated technology and trend analysis.

Between the lines: - The market story is less about one drug alone and more about a broader shift toward mutation-specific treatment in rare disease. - The emphasis on screening, diagnostics and regulatory support suggests future growth depends as much on identifying eligible patients as on drug innovation. - North America’s lead and Europe’s expected acceleration point to a market shaped by reimbursement, regulation and healthcare infrastructure.

What's next: - The report expects growth to continue through 2035 as exon-skipping, gene-based and personalized therapies expand. - Europe’s rare-disease investment and regulatory incentives could narrow the gap with North America. - Wider newborn screening and earlier diagnosis could increase the pool of patients eligible for exon 45-targeted treatment. - The Business Research Company says readers can contact Saumya Sahay for more information at marketing@tbrc.info or the listed regional phone numbers.

The bottom line: - Amondys 45 sits at the intersection of rare-disease demand, precision medicine and improving diagnostics, and that combination is driving the market outlook through the next decade.